Rgenix is a privately-held clinical-stage biopharmaceutical company developing first-in-class drugs that target key pathways in cancer progression.

310 E 67th St, Suite 1-12‎, New York, NY 10065
(646) 856-9261
[email protected]

Peter Van Vlasselaer, PhD

Independent Board Director

Peter Van Vlasselaer, PhD has over 30 years of experience in the biotech industry. He was most recently the Founder, President and Chief Executive Officer of ARMO Biosciences, which shortly after its public offering (ARMO) was acquired by Eli Lilly. Before that, he was President and Chief Executive Officer of iPierian (acquired by BMS), ARRESTO (acquired by Gilead) and AVIDIA (acquired by AMGEN).

In addition to founding ARMO, he was the founder of ARRESTO, co-founder and Executive Chair of TrueNorth (acquired by Bioverativ) and he was a member of the start-up teams of InterMune (ITMN) and Dendreon (DNDN). He was involved in the development of several products, some of which obtained regulatory approval (Provenge, Actimmune, Esbriet, Enjaymo).

He currently serves on the boards of Asceneuron and Inspirna . Dr. Van Vlasselaer has a degree in Zoology and a PhD in Immunology from the Catholic University of Leuven, Belgium. He was a Post-Doctoral Fellow in the Division of Immunology and Rheumatology at Stanford University Medical School and DNAX Research Institute. Dr. Van Vlasselaer has authored several peer reviewed scientific publications and book chapters and he is an inventor on multiple patents.